<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403429</url>
  </required_header>
  <id_info>
    <org_study_id>MITO-6</org_study_id>
    <secondary_id>EudraCT number 2006-001724-40</secondary_id>
    <nct_id>NCT00403429</nct_id>
  </id_info>
  <brief_title>MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer</brief_title>
  <official_title>Phase II Study With Capecitabine as Monotherapy in the Treatment of Platinum Resistant or Refractory Ovarian Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the activity and the toxicity of capecitabine as
      monotherapy in the treatment of platinum resistant or refractory ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian cancer is the second most frequent and the most deadly gynaecologic cancer. Standard
      combination chemotherapy with a platinum derivative (cisplatin or carboplatin) and a taxane
      are effective in causing remission in 60 - 80 % of cases, yet recurrences are frequent and
      5-year survival is only 20%. Current therapies for second line treatment of recurrence in
      patients who have platinum refractory (who experienced progression of the disease during
      first line platinum based therapy) or platinum resistant (who experienced a recurrence of the
      disease within 6 months of completing platinum based therapy)ovarian cancer are limited.
      Capecitabine, an oral chemotherapy already used in colon and breast cancers, has shown some
      promise in early clinical trials for treating recurrent ovarian cancer.

      Patients entered into this trial will receive oral capecitabine 1250 mg/m2 on days 1-14 every
      21 days for up to 6 cycles, depending on response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>toxicity</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologic or histologic diagnosis of relapsed ovarian cancer

          -  Refractory or resistant to platinum salts disease

          -  Age &lt; 75 years

          -  At least one measurable lesion (³ 20 mm with conventional techniques or ³ 10 mm with
             spiral CT scan)

          -  Life expectancy of at least 3 months

          -  Written informed consent

        Exclusion Criteria:

          -  Previous or concomitant malignant neoplasia within 5 years prior to basal evaluation
             (excluding adequately treated basocellular or spinocellular skin carcinoma or in situ
             carcinoma of the uterine cervix).

          -  Performance Status (ECOG) ³ 3

          -  Previous chemotherapy treatment with capecitabine

          -  More than 3 lines of chemotherapy

          -  Heart disease (heart failure, heart attack during the 6 months prior to the trial,
             atrioventricular block of any degree, serious arrhythmia)

          -  Leukocytes &lt; 4000/mm3, platelets &lt; 100000/mm3

          -  Modifications of renal function (Creatinine ³ 1.25 times the upper normal limit) or
             liver function (SGOT or SGPT ³ 1.25 times the upper normal limit)

          -  Present or suspected haemorrhagic syndromes

          -  Uncooperative and/or unreliable patients

          -  Patients' inability to access the centre
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Malzoni, Reparto di Ginecologia Oncologica</name>
      <address>
        <city>Avellino</city>
        <state>AV</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Miulli, Divisione Medicina Interna Sezione Oncologica</name>
      <address>
        <city>Acquaviva delle Fonti</city>
        <state>BA</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Oncologico Bari, Oncologia Medica</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli, U.O. di Oncologia</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cannizzaro, Divisione di Ostetricia e Ginecologia</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Solllievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Carlo Poma, Divisione di Oncologia ed Ematologia</name>
      <address>
        <city>Mantova</city>
        <state>MN</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ramazzini, Day Hospital Oncologico</name>
      <address>
        <city>Carpi</city>
        <state>MO</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario P. Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Massimo, Day Hospital Oncologico</name>
      <address>
        <city>Penne</city>
        <state>PE</state>
        <zip>65017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico, Divisione di Oncolgia Medica C</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Maria degli Angeli, Servizio di Oncologia</name>
      <address>
        <city>Pordenone</city>
        <state>PN</state>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Bortolo ULSS 6, U.O. di Oncologia Medica</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Calibita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Pisano C, Morabito A, Sorio R, Breda E, Lauria R, Gebbia V, Scaltriti L, Scalone S, Zagonel V, Greggi S, Beneduce G, Losito S, Gallo C, Di Maio M, Forestieri V, Pignata S. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. Cancer Chemother Pharmacol. 2009 Oct;64(5):1021-7. doi: 10.1007/s00280-009-0958-0. Epub 2009 Mar 6.</citation>
    <PMID>19266200</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2006</study_first_submitted>
  <study_first_submitted_qc>November 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2006</study_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral chemotherapy</keyword>
  <keyword>platinum resistant</keyword>
  <keyword>platinum refractory</keyword>
  <keyword>second line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

